The VAFs of RUNX1 remained unchanged in the two MDS cases (median 44% (first) vs. 44.5% (follow-up)) and showed an increase in MDS-IB/EB cases (median 7% vs. 11%). This evidence concerns the gene RUNX1 and myelodysplastic syndrome.